Drug Guidance for Subsidy 17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease The Ministry of Health’s Drug Advisory Committee has recommended: Fluticasone furoate/umeclid... See all × 17/02/2025 Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease The Ministry of Health’s Drug Advisory Committee has recommended: Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder for treating asthma; and Fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) inhalation powder for treating chronic obstructive pulmonary disease. Funding status RFluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta) 100/62.5/25 mcg (30 inhalations) and 200/62.5/25 mcg (30 inhalations) inhalation powder are recommended for inclusion on the Standard Drug List (SDL) for the abovementioned indications from 1 April 2025. NRSDL subsidy does not apply to any formulations or strengths of beclomethasone dipropionate/glycopyrronium/formoterol, budesonide/glycopyrronium/formoterol, mometasone furoate/glycopyrronium/indacaterol, or tiotropium.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Aerosol, Metered, Beclomethasone Dipropionate Anhydrous 0.1 mg/actuation + Formoterol Fumarate Dihydrate 0.006 mg/actuation + Glycopyrronium Bromide 0.0125 mg/actuation Changi General Hospital Sengkang General Hospital Singapore General Hospital Woodlands Health Campus
RESPIRATORY (INHALATION) Select a brand starting with the letter: T TRIMBOW PRESSURISED INHALATION SOLUTION 100/6/12.5 μG PER ACTUATION [SIN15924P]